Why take the continuous route? Because it leads to better, faster bioprocessing.
Sponsored By
Why adopt continuous bioprocessing? Because it can lead to faster and more cost-effective biopharma manufacturing. In this supplement, Pall and their collaborators discuss the benefits of continuous bioprocessing and how Pall is innovating in this area.
Receive the latest pharmaceutical news, personalities, education, and career development – weekly to your inbox.
August 31, 2026
4 min read
New approaches to oligonucleotide production, mRNA design, and supply chain control could help turn promising nucleic acid therapies into scalable commercial products
August 27, 2026
9 min read
Why preserving samples is a scientific, regulatory, and operational challenge – and what’s at risk when it goes wrong
August 26, 2026
9 min read
Jon Rees sees signs of recovery following biotech's post-pandemic funding reset, but there’s no going back to the “old normal”
August 26, 2026
7 min read
Merck and Moderna report positive phase III results for intismeran in melanoma, as The Medicine Maker revisits how cancer vaccines work and the challenges still facing the field